A Phase 1/2 interventional study of Epacadostat and Nivolumab in Solid Tumors, sponsored by Incyte Corporation. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-28.
Sponsored by Incyte Corporation · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies in Melanoma by Incyte Corporation — none open to participants now, none under way, none of them phase 3. Melanoma · Incyte Corporation.
Among the 20 studies in Melanoma by Incyte Corporation, this one is the 17th largest by enrollment, is one of 4 that started in 2018, is one of 11 in phase 1/2, and was the 11th registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →None of the 20 studies in Melanoma by Incyte Corporation is open now. The open studies under Melanoma, anywhere →
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 14 · Phase 3 1
First in 2012; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 40 across 2,652 interventional studies indexed under Melanoma.
Median enrollment 57 across the 20 interventional studies. Of the 20 that completed or were terminated, 13 (65%) have results posted.
This tab as a report to print or save as PDF → With an account.
Incyte Corporation is the lead sponsor of 288 studies on the registry; 33 are open to participants now.
Of its 149 completed or terminated interventional studies of FDA-regulated products, 95 (64%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 20 studies in Melanoma by Incyte Corporation, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine the safety, tolerability, and efficacy of epacadostat when given in combination with nivolumab and ipilimumab, and in combination with nivolumab and lirilumab, in participant with advanced or metastatic malignancies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
Drug: Epacadostat · Drug: Nivolumab · Drug: Ipilimumab
Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of each 14 day cycle and ipilimumab 1 mg/kg intravenous (IV) every 6 weeks thereafter on Day 1 of every third treatment cycle until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
Drug: Epacadostat · Drug: Nivolumab · Drug: Ipilimumab
Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 50 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
Drug: Epacadostat · Drug: Nivolumab · Drug: Lirilumab
Participants with advanced or metastatic solid tumor who have received no more than 2 prior treatment regimens received epacadostat 100 mg BID orally in combination with nivolumab 240 mg on day 1 of every 14 day cycle and lirilumab 240 mg IV every 4 weeks until disease progression or occurrence of unacceptable drug-related toxicities or discontinuation or up to 24 months.
Drug: Epacadostat · Drug: Nivolumab · Drug: Lirilumab
Participants with unresectable or metastatic melanoma (MEL) were planned to be included in this cohort, who did not receive prior systemic therapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.
Drug: Epacadostat · Drug: Nivolumab · Drug: Ipilimumab
Participants with advanced or metastatic non-small cell lung cancer (NSCLC) were planned to be included in this cohort, who have received no more than 1 prior line of platinum-based chemotherapy for advanced or metastatic disease to receive epacadostat in combination with nivolumab and ipilimumab at the MTD/PAD determined from dose escalation phase.
Drug: Epacadostat · Drug: Nivolumab · Drug: Ipilimumab
Participants with recurrent or metastatic serotonin norepinephrine reuptake inhibitor (SCCHN) were planned to be included in this cohort, who received no more than 1 prior line of platinum-based chemotherapy for recurrent or metastatic disease to receive epacadostat in combination with nivolumab and lirilumab at the MTD/PAD determined from dose escalation phase.
Drug: Epacadostat · Drug: Nivolumab · Drug: Lirilumab
Phase 1: Epacadostat at the protocol-defined dose twice daily. Phase 2: Epacadostat at the recommended dose from Phase 1.
Also known as: INCB024360
Nivolumab at the protocol-specified dose and schedule.
Also known as: Opdivo®, BMS-936558
Ipilimumab at the protocol-specified dose and schedule.
Also known as: Yervoy®, BMS-734016
Lirilumab at the protocol-specified dose and schedule.
Also known as: IPH2102, BMS-986015
Phase 1: Percentage of Participants With At Least One Treatment Emergent Adverse Events (TEAEs)
A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment. AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.
Time frame: Screening through up to 100 days after end of treatment, up to approximately 24 months
Phase 2: Objective Response Rate (ORR) Based on Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)
ORR was defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)
Phase 1: Objective Response Rate (ORR) Based on RECIST v1.1
ORR was defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)
Phase 1: Duration of Response (DOR)
DOR was defined as the time from the earliest date of CR or PR until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.
Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)
Phase 1: Progression-free Survival (PFS)
PFS was defined as the time from the start of combination therapy until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.
Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)
Phase 2: Duration of Response (DOR)
DOR was defined as the time from the earliest date of CR or PR until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.
Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)
Phase 2: Progression-free Survival (PFS)
PFS was defined as the time from the start of combination therapy until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.
Time frame: Every 8 weeks for the first 12 months and then every 12 weeks thereafter up to end of treatment (Up to Month 24)
Phase 2: Percentage of Participants With Treatment Emergent Adverse Events (TEAEs)
A TEAE was any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment. AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.
Time frame: Screening through up to 100 days for treatment Group A and 150 days for treatment Group B after end of treatment, up to approximately 24 months
Participants took part at 4 study centers in the United States from 21 March 2018 to 29 January 2021.
| Milestone | Phase 1: Dose Escalataion: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Escalation: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | Phase 1: Dose Escalation: Treatment Group B: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Escalation: Treatment Group B: Cohort 2 Epacadostat 100 mg BID | Phase 2: Dose Expansion: Treatment Group A: Cohort A1 | Phase 2: Dose Expansion: Treatment Group A: Cohort A2 | Phase 2: Dose Expansion: Treatment Group B: Cohort B1 |
|---|---|---|---|---|---|---|---|
| Started | 5 | 6 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 5 | 6 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 1 | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Reason not specified | 3 | 4 | 0 | 0 | 0 | 0 | 0 |
A TEAE is any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment. AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.
| percentage of participants | Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID |
|---|---|---|
| Phase 1: Percentage of Participants With At Least One Treatment Emergent Adverse Events (TEAEs) | 100 | 100 |
ORR was defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
No measurements were reported for this outcome.
ORR was defined as the percentage of participants with confirmed objective response (OR). Confirmed OR is defined as complete response (CR) or partial response (PR) on two consecutive occasions ≥ 4 weeks apart, as determined by the investigator according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. CR is defined as disappearance of all target lesions. PR is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum of diameters.
No measurements were reported for this outcome.
DOR was defined as the time from the earliest date of CR or PR until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.
No measurements were reported for this outcome.
PFS was defined as the time from the start of combination therapy until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.
No measurements were reported for this outcome.
DOR was defined as the time from the earliest date of CR or PR until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.
No measurements were reported for this outcome.
PFS was defined as the time from the start of combination therapy until the earliest date at which progression criteria are met as determined by investigator evaluation of radiographic disease assessment per RECIST v1.1, or date of death due to any cause. Disease progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study including baseline; or the appearance of one or more new lesions.
No measurements were reported for this outcome.
A TEAE was any AE either reported for the first time or worsening of a pre-existing event after first dose of study treatment. AE is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related, that occurs after a participant provides informed consent.
No measurements were reported for this outcome.
Collected over Screening through up to 100 days after end of treatment, up to approximately 24 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | 1/5 (20%) | 2/5 (40%) | 5/5 (100%) |
| Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | 2/6 (33.3%) | 3/6 (50%) | 6/6 (100%) |
| Total | 3/11 (27.3%) | 5/11 (45.5%) | 11/11 (100%) |
| Event | Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | Total |
|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/5 | 0/6 | 1/11 |
| Atrial fibrillationCardiac disorders | 1/5 | 0/6 | 1/11 |
| PolyarthritisMusculoskeletal and connective tissue disorders | 1/5 | 0/6 | 1/11 |
| Acute myocardial infarctionCardiac disorders | 0/5 | 1/6 | 1/11 |
| DehydrationMetabolism and nutrition disorders | 0/5 | 1/6 | 1/11 |
| DiarrhoeaGastrointestinal disorders | 0/5 | 1/6 | 1/11 |
| DuodenitisGastrointestinal disorders | 0/5 | 1/6 | 1/11 |
| HypokalaemiaMetabolism and nutrition disorders | 0/5 | 1/6 | 1/11 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 0/5 | 1/6 | 1/11 |
| Lung infectionInfections and infestations | 0/5 | 1/6 | 1/11 |
| Event | Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | Total |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 3/5 | 1/6 | 4/11 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/5 | 0/6 | 2/11 |
| FatigueGeneral disorders | 2/5 | 1/6 | 3/11 |
| HypokalaemiaMetabolism and nutrition disorders | 2/5 | 1/6 | 3/11 |
| HypothyroidismEndocrine disorders | 2/5 | 2/6 | 4/11 |
| Lipase increasedInvestigations | 2/5 | 1/6 | 3/11 |
| RashSkin and subcutaneous tissue disorders | 2/5 | 1/6 | 3/11 |
| PruritusSkin and subcutaneous tissue disorders | 1/5 | 2/6 | 3/11 |
| Pruritus generalisedSkin and subcutaneous tissue disorders | 1/5 | 2/6 | 3/11 |
| Urinary tract infectionInfections and infestations | 1/5 | 2/6 | 3/11 |
Full analysis set included all participants enrolled in the study who received at least 1 dose of combination therapy.
| Age, Continuous(years) | Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | Total |
|---|---|---|---|
| Mean | 65.4 ± 8.79 | 53.8 ± 8.57 | 59.1 ± 10.20 |
| Sex: Female, Male(Participants) | Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | Total |
|---|---|---|---|
| Female | 2 | 3 | 5 |
| Male | 3 | 3 | 6 |
| Ethnicity (NIH/OMB)(Participants) | Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 |
| Not Hispanic or Latino | 3 | 5 | 8 |
| Unknown or Not Reported | 2 | 1 | 3 |
| Race (NIH/OMB)(Participants) | Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 1 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 5 | 5 | 10 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Weight(kilogram (kg)) | Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | Total |
|---|---|---|---|
| Mean | 90.464 ± 16.3665 | 81.255 ± 26.5702 | 85.441 ± 21.9832 |
| Height(centimeter (cm)) | Phase 1: Dose Escalation: Treatment Group A: Cohort 1 Epacadostat 50 mg BID | Phase 1: Dose Esclataion: Treatment Group A: Cohort 2 Epacadostat 100 mg BID | Total |
|---|---|---|---|
| Mean | 173.2 ± 9.20 | 174.2 ± 3.25 | 173.7 ± 6.28 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2018 to primary completion in Jan 2021, 34 months.
Results were first posted in Feb 2022, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epacadostat